Tezepelumab decreases exacerbation rate, improves lung funct

Tezepelumab decreases exacerbation rate, improves lung function, quality of life in COPD

SAN DIEGO — Among patients with moderate to very severe COPD receiving tezepelumab vs. placebo, the annualized rate of exacerbations dropped by 17%, according to research presented at the American Thoracic Society International Conference.“Tezepelumab is a monoclonal antibody that specifically blocks [thymic stromal lymphopoietin] from interacting with its receptor,” Dave Singh,

Related Keywords

United States , Becs , Wien , Austria , San Diego , California , American , Robert Fogel , Byisabella Hornick , Dave Singh , Kristen Dowd , Astrazeneca , Amgen , University Of Manchester , American Thoracic Society International Conference , American Thoracic Society International , Respiratory Questionnaire ,

© 2025 Vimarsana